Preoperative Chemotherapy for Operable Breast Cancer
During the past 25 years, there has been a significant change in the way in which operable breast cancer is managed. As a result of laboratory and clinical investigations conducted during the 1960s, evidence was obtained that challenged Halstedian principles of tumor dissemination and provided support for an alternative hypothesis.1 Findings from subsequent randomized clinical trials demonstrated that the extent of surgical resection had no effect on the patient’s outcome2 and that the administration of systemic therapy after surgery significantly improved the disease-free survival (DFS) and survival of such patients.3 Consequently, there was a shift in emphasis away from surgery as the sole treatment for breast cancer, and systemic therapy became an integral part of the management of the disease.
KeywordsBreast Cancer Fine Needle Aspiration Preoperative Chemotherapy Pathologic Complete Response Postoperative Chemotherapy
Unable to display preview. Download preview PDF.
- 3.Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet; 339:1–15 (Part 1 ), 71–85 (Part 2), 1992.Google Scholar
- 12.Schick P, Goodstein J, Moor J, et al: Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol; 22: 278282, 1983.Google Scholar
- 14.Fisher B, Redmond C, Poisson R, et al: Eight-year results of a randomized clinical trial comparing mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med; 320: 820–828, 1989.Google Scholar
- 18.Tubiana-Hulin M, Malek M, Briffod M, et al: Preoperative chemotherapy of operable breast cancer (stage IIIA). Prognostic factors of distant recurrence. Eur J Cancer; Vol. 29A, Suppl. 6: S76 0391 ), 1993.Google Scholar
- 20.Smith IE, Jones AL, O’Brien MER, et al: Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer; Vol. 29A, 12: 17961799, 1993.Google Scholar
- 25.Fisher B, Rockette H, Robidoux A, et al: Effect of preoperative therapy for breast cancer (BC) on local-regional disease: First report of NSABP B-18. Proc Am Soc Clin Oncol; 13: 64, 1994.Google Scholar
- 29.Mamounas EP: NSABP Protocol B-27: preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology; Suppl. 6: 37–40, 1997.Google Scholar